1
|
Sheikhi M, Nemayandeh N, Shirangi M. Peptide Acylation in Aliphatic Polyesters: a Review of Mechanisms and Inhibition Strategies. Pharm Res 2024; 41:765-778. [PMID: 38504074 DOI: 10.1007/s11095-024-03682-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 02/24/2024] [Indexed: 03/21/2024]
Abstract
Biodegradable polyesters are widely employed in the development of controlled release systems for peptide drugs. However, one of the challenges in developing a polyester-based delivery system for peptides is the acylation reaction between peptides and polymers. Peptide acylation is an important factor that affects formulation stability and can occur during storage, in vitro release, and after drug administration. This review focuses on the mechanisms and parameters that influence the rate of peptide acylation within polyesters. Furthermore, it discusses reported strategies to minimize the acylation reaction.
Collapse
Affiliation(s)
- Mojgan Sheikhi
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Tehran, Iran
| | - Nasrin Nemayandeh
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Tehran, Iran
| | - Mehrnoosh Shirangi
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Tehran, Iran.
| |
Collapse
|
2
|
Sheikhi M, Sharifzadeh M, Hennink WE, Firoozpour L, Hajimahmoodi M, Khoshayand MR, Shirangi M. Design of experiments approach for the development of a validated method to determine the exenatide content in poly(lactide-co-glycolide) microspheres. Eur J Pharm Biopharm 2023; 192:56-61. [PMID: 37783361 DOI: 10.1016/j.ejpb.2023.09.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2023] [Revised: 09/20/2023] [Accepted: 09/29/2023] [Indexed: 10/04/2023]
Abstract
Due to the lack of pharmacopeia guidelines for injectable microspheres based on poly (D, L-lactide-co-glycolide) (PLGA), an internal method validation is a critical prerequisite for quality assurance. One of the essential issues of developing peptide-based drugs loaded PLGA microspheres is the precise determination of the amount of peptide drug entrapped in the microspheres. The aim of this study is the development and optimization of a method for measuring the drug content loading of PLGA microspheres using exenatide as a model peptide drug. Exenatide-loaded PLGA microspheres were prepared by a double emulsion solvent evaporation method. The extraction method to determine exenatide content in microspheres was optimized using Design of Experiments (DoE) approach. After the initial screening of six factors, using Fractional Factorial design (FFD), four of them, including type of organic solvent, buffer/organic solvent ratio (v/v), shaking time and pH, exhibited significant effects on the response, namely the exenatide loading, and a Box-Behnken design (BBD) was subsequently applied to obtain its optimum level. The optimum level for organic solvent volume, buffer/organic solvent ratio, shaking time, and pH were 4 ml, 1, 5.6 hrs, and pH 6, respectively. The exenatide content in microspheres under these conditions was 6.4 ± 0.0 (%w/w), whereas a value of 6.1% was predicted by the derived equation. This excellent agreement between the actual and the predicted value demonstrates that the fitted model can thus be used to determine the exenatide content.
Collapse
Affiliation(s)
- Mojgan Sheikhi
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Iran
| | - Mohammad Sharifzadeh
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Loghman Firoozpour
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran
| | - Mannan Hajimahmoodi
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Iran
| | - Mohammad Reza Khoshayand
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Iran.
| | - Mehrnoosh Shirangi
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Science Tehran, Iran.
| |
Collapse
|
3
|
Shukla A, Maiti P. Nanomedicine and versatile therapies for cancer treatment. MedComm (Beijing) 2022; 3:e163. [PMID: 35992969 PMCID: PMC9386439 DOI: 10.1002/mco2.163] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 06/11/2022] [Accepted: 06/14/2022] [Indexed: 12/19/2022] Open
Abstract
The higher prevalence of cancer is related to high rates of mortality and morbidity worldwide. By virtue of the properties of matter at the nanoscale, nanomedicine is proven to be a powerful tool to develop innovative drug carriers with greater efficacies and fewer side effects than conventional therapies. In this review, different nanocarriers for controlled drug release and their routes of administration have been discussed in detail, especially for cancer treatment. Special emphasis has been given on the design of drug delivery vehicles for sustained release and specific application methods for targeted delivery to the affected areas. Different polymeric vehicles designed for the delivery of chemotherapeutics have been discussed, including graft copolymers, liposomes, hydrogels, dendrimers, micelles, and nanoparticles. Furthermore, the effect of dimensional properties on chemotherapy is vividly described. Another integral section of the review focuses on the modes of administration of nanomedicines and emerging therapies, such as photothermal, photodynamic, immunotherapy, chemodynamic, and gas therapy, for cancer treatment. The properties, therapeutic value, advantages, and limitations of these nanomedicines are highlighted, with a focus on their increased performance versus conventional molecular anticancer therapies.
Collapse
Affiliation(s)
- Aparna Shukla
- School of Materials Science and TechnologyIndian Institute of Technology (Banaras Hindu University)VaranasiIndia
| | - Pralay Maiti
- School of Materials Science and TechnologyIndian Institute of Technology (Banaras Hindu University)VaranasiIndia
| |
Collapse
|
4
|
Alshaikh RA, Waeber C, Ryan KB. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies. Adv Drug Deliv Rev 2022; 187:114342. [PMID: 35569559 DOI: 10.1016/j.addr.2022.114342] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 04/28/2022] [Accepted: 05/09/2022] [Indexed: 12/12/2022]
Abstract
There is an increasing momentum in research and pharmaceutical industry communities to design sustained, non-invasive delivery systems to treat chronic neovascular ocular diseases that affect the posterior segment of the eye including age-related macular degeneration and diabetic retinopathy. Current treatments include VEGF blockers, which have revolutionized the standard of care for patients, but their maximum therapeutic benefit is hampered by the need for recurrent and invasive administration procedures. Currently approved delivery systems intended to address these limitations exploit polymer technology to regulate drug release in a sustained manner. Here, we critically review sustained drug delivery approaches for the treatment of chronic neovascular diseases affecting the ocular posterior segment, with a special emphasis on novel and polymeric technologies spanning the spectrum of preclinical and clinical investigation, and those approved for treatment. The mechanism by which each formulation imparts sustained release, the impact of formulation characteristics on release and foreign body reaction, and special considerations related to the translation of these systems are discussed.
Collapse
Affiliation(s)
| | - Christian Waeber
- School of Pharmacy, University College Cork, Cork, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
| | - Katie B Ryan
- School of Pharmacy, University College Cork, Cork, Ireland; SSPC The SFI Research Centre for Pharmaceuticals, School of Pharmacy, University College Cork, Ireland.
| |
Collapse
|
5
|
Zuglianello C, Lemos-Senna E. The nanotechnological approach for nasal delivery of peptide drugs: a comprehensive review. J Microencapsul 2022; 39:156-175. [PMID: 35262455 DOI: 10.1080/02652048.2022.2051626] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
This review gathers recent studies, patents, and clinical trials involving the nasal administration of peptide drugs to supply a panorama of developing nanomedicine advances in this field. Peptide drugs have been featured in the pharmaceutical market, due to their high efficacy, biological activity, and low immunogenicity. Pharmaceutical industries need technology to circumvent issues relating to peptide stability and bioavailability. The oral route offers very harsh and unfavourable conditions for peptide administration, while the parenteral route is inconvenient and risky for patients. Nasal administration is an attractive alternative, mainly when associated with nanotechnological approaches. Nanomedicines may improve the nasal administration of peptide drugs by providing protection for the macromolecules from enzymes while also increasing their time of retention and permeability in the nasal mucosa. Nanomedicines for nasal administration containing peptide drugs have been acclaimed for both prevention, and treatment, of infections, including the pandemic COVID-19, cancers, metabolic and neurodegenerative diseases.
Collapse
Affiliation(s)
- Carine Zuglianello
- Pharmaceutical Nanotechnology Post-Graduation Program, University of Santa Catarina, Florianópolis, Brazil
| | - Elenara Lemos-Senna
- Pharmaceutical Nanotechnology Post-Graduation Program, University of Santa Catarina, Florianópolis, Brazil
| |
Collapse
|
6
|
Vlachopoulos A, Karlioti G, Balla E, Daniilidis V, Kalamas T, Stefanidou M, Bikiaris ND, Christodoulou E, Koumentakou I, Karavas E, Bikiaris DN. Poly(Lactic Acid)-Based Microparticles for Drug Delivery Applications: An Overview of Recent Advances. Pharmaceutics 2022; 14:359. [PMID: 35214091 PMCID: PMC8877458 DOI: 10.3390/pharmaceutics14020359] [Citation(s) in RCA: 61] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 01/27/2022] [Accepted: 01/31/2022] [Indexed: 11/23/2022] Open
Abstract
The sustained release of pharmaceutical substances remains the most convenient way of drug delivery. Hence, a great variety of reports can be traced in the open literature associated with drug delivery systems (DDS). Specifically, the use of microparticle systems has received special attention during the past two decades. Polymeric microparticles (MPs) are acknowledged as very prevalent carriers toward an enhanced bio-distribution and bioavailability of both hydrophilic and lipophilic drug substances. Poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and their copolymers are among the most frequently used biodegradable polymers for encapsulated drugs. This review describes the current state-of-the-art research in the study of poly(lactic acid)/poly(lactic-co-glycolic acid) microparticles and PLA-copolymers with other aliphatic acids as drug delivery devices for increasing the efficiency of drug delivery, enhancing the release profile, and drug targeting of active pharmaceutical ingredients (API). Potential advances in generics and the constant discovery of therapeutic peptides will hopefully promote the success of microsphere technology.
Collapse
Affiliation(s)
- Antonios Vlachopoulos
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Georgia Karlioti
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Evangelia Balla
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Vasileios Daniilidis
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Theocharis Kalamas
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Myrika Stefanidou
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Nikolaos D. Bikiaris
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Evi Christodoulou
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Ioanna Koumentakou
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| | - Evangelos Karavas
- Pharmathen S.A., Pharmaceutical Industry, Dervenakion Str. 6, Pallini Attikis, GR-153 51 Attiki, Greece
| | - Dimitrios N. Bikiaris
- Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece; (A.V.); (G.K.); (E.B.); (V.D.); (T.K.); (M.S.); (N.D.B.); (E.C.); (I.K.)
| |
Collapse
|
7
|
Poly(Lactic-co-glycolic) Acid and Phospholipids Hybrid Nanoparticles for Regeneration of Biological Tissue. CHEMENGINEERING 2022. [DOI: 10.3390/chemengineering6010010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In tissue regeneration, biomaterials facilitate biological processes. However, a treatment with biomaterials will be successful only if supported by simple and inexpensive technologies which stimulate the regenerative processes. The present study focused on the possibility of creating formulations from which then to obtain suitable materials for the regeneration of heart tissue. The experimental procedure for precipitation of polymer- nanoparticles was modified ad hoc to obtain hybrid poly lactic-co-glycolic acid (PLGA)-phospholipid nanoparticles. The properties of the formulations produced by direct PLGA-phospholipid co-precipitation depend on the mass ratio R= polymer mass/phospholipid mass. The value of this parameter allows us to modulate the properties of the formulations. Formulations with R = 1.5, 2.3, 4, and 9 were prepared, and for each of them the particle-size distribution obtained by dynamic light scattering was studied. All samples showed that the hydrodynamic diameter decreases with increasing R value. This behavior is interpreted as polymer coil shrinkage due to contacts with the non-solvent. The spreadability and ease of obtaining thin sheets were evaluated for each formulation. The formulation with R=4 resulted in a homogeneous and easily workable material in thin sheets.
Collapse
|
8
|
van der Kooij RS, Steendam R, Frijlink HW, Hinrichs WLJ. An overview of the production methods for core-shell microspheres for parenteral controlled drug delivery. Eur J Pharm Biopharm 2021; 170:24-42. [PMID: 34861359 DOI: 10.1016/j.ejpb.2021.11.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 10/19/2021] [Accepted: 11/26/2021] [Indexed: 01/25/2023]
Abstract
Core-shell microspheres hold great promise as a drug delivery system because they offer several benefits over monolithic microspheres in terms of release kinetics, for instance a reduced initial burst release, the possibility of delayed (pulsatile) release, and the possibility of dual-drug release. Also, the encapsulation efficiency can significantly be improved. Various methods have proven to be successful in producing these core-shell microspheres, both the conventional bulk emulsion solvent evaporation method and methods in which the microspheres are produced drop by drop. The latter have become increasingly popular because they provide improved control over the particle characteristics. This review assesses various production methods for core-shell microspheres and summarizes the characteristics of formulations prepared by the different methods, with a focus on their release kinetics.
Collapse
Affiliation(s)
- Renée S van der Kooij
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| | - Rob Steendam
- InnoCore Pharmaceuticals, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands
| | - Henderik W Frijlink
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| | - Wouter L J Hinrichs
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| |
Collapse
|
9
|
Grudén S, Brunmark C, Holmqvist B, Brenndörfer ED, Johansson M, Liu J, Zhao Y, Axén N, Hassan M. Biodistribution of fluorescence-labelled EGF protein from slow release NanoZolid depots in mouse. Int J Pharm 2021; 601:120588. [PMID: 33845148 DOI: 10.1016/j.ijpharm.2021.120588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 03/05/2021] [Accepted: 04/06/2021] [Indexed: 10/21/2022]
Abstract
AIM The study was designed to evaluate the ability of the calcium sulfate based NanoZolid® drug delivery technology to locally release the epidermal growth factor (EGF) protein while maintaining its biological activity. METHODS NanoZolid-formulated EGF protein labelled with a near infrared dye (EGF-NIR) depots or EGF-NIR dissolved in PBS were injected subcutaneously into mice bearing EGF receptor (EGFR) positive human A549 lung cancer tumors inoculated subcutaneously. The release and biodistribution of the EGF-NIR were investigated in vivo longitudinally up to 96 h post administration, utilizing whole body fluorescence imaging. In order to confirm the in vivo findings, histological analysis of tumor cryosections was performed to investigate EGF-NIR fluorescent signal and EGFR expression level by immunofluorescence labelling. RESULTS The in vivo fluorescence imaging showed a controlled release profile of the EGF-NIR loaded in the NanoZolid depots compared to free EGF-NIR. Histological analysis of the tumors further demonstrated a prevailing distribution of EGF-NIR in regions with high levels of EGFR expression. CONCLUSION Calcium sulfate based depots can be used to formulate EGF while maintaining its biological activity, e.g. receptor binding capability. This may have a good clinical potential for local delivery of biomolecules to enhance treatment efficacy and minimize systemic adverse effects.
Collapse
Affiliation(s)
- Stefan Grudén
- Experimental Cancer Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, Sweden; LIDDS AB, Virdings allé 32B, SE-754 50 Uppsala, Sweden.
| | - Charlott Brunmark
- Truly Labs AB, Medicon Village, Scheelevägen 2, SE-223 81 Lund, Sweden.
| | - Bo Holmqvist
- ImaGene-iT AB, Medicon Village, Scheelevägen 2, SE-223 81 Lund, Sweden.
| | | | | | - Jian Liu
- Truly Labs AB, Medicon Village, Scheelevägen 2, SE-223 81 Lund, Sweden.
| | - Ying Zhao
- Experimental Cancer Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, Sweden; Clinical Research Center (KFC) and Center for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden.
| | - Niklas Axén
- LIDDS AB, Virdings allé 32B, SE-754 50 Uppsala, Sweden.
| | - Moustapha Hassan
- Experimental Cancer Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, Sweden; Clinical Research Center (KFC) and Center for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden.
| |
Collapse
|
10
|
Markwalter CE, Pagels RF, Hejazi AN, Ristroph KD, Wang J, Chen K, Li J, Prud'homme RK. Sustained release of peptides and proteins from polymeric nanocarriers produced by inverse Flash NanoPrecipitation. J Control Release 2021; 334:11-20. [PMID: 33823220 DOI: 10.1016/j.jconrel.2021.04.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 03/31/2021] [Accepted: 04/02/2021] [Indexed: 12/18/2022]
Abstract
Peptide and protein therapeutics generally exhibit high potency and specificity and are increasingly important segments of the pharmaceutical market. However, their clinical applications are limited by rapid clearance and poor membrane permeability. Encapsulation of the peptide or protein into a nano-scale carrier can modify its pharmacokinetics and biodistribution. This might be employed to promote uptake in desired cell types or tissues, to limit systemic exposure, or to reduce the need for frequent injections. We have recently described inverse Flash NanoPrecipitation (iFNP), a scalable technique to encapsulate water-soluble therapeutics into polymeric nanocarriers, and have demonstrated improvements in therapeutic loading of an order of magnitude over comparable approaches. Here, we describe the formulation parameters that control release rates of encapsulated model therapeutics polymyxin B, lysozyme, and bovine serum albumin from nanocarriers produced using iFNP. Using a neutropenic lung infection mouse model with a multi-drug resistant Acinetobacter baumannii clinical isolate, we demonstrate enhanced therapeutic effect and safety profile afforded by nanocarrier-encapsulated polymyxin B following pulmonary administration. The encapsulated formulation reduced toxicity observed at elevated doses and resulted in up to 2.7-log10 reduction in bacterial burden below that of unencapsulated polymyxin B. These results establish the promise of iFNP as a platform for nanocarrier delivery of water-soluble therapeutics.
Collapse
Affiliation(s)
- Chester E Markwalter
- Dept of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA
| | - Robert F Pagels
- Dept of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA
| | - Ava N Hejazi
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton, Melbourne, Victoria 3800, Australia
| | - Kurt D Ristroph
- Dept of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA
| | - Jiping Wang
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton, Melbourne, Victoria 3800, Australia
| | - Ke Chen
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton, Melbourne, Victoria 3800, Australia
| | - Jian Li
- Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton, Melbourne, Victoria 3800, Australia
| | - Robert K Prud'homme
- Dept of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA.
| |
Collapse
|
11
|
Antonov EN, Bogorodsky SE, Dunaev AG, Krotova LI, Mariyanats AO, Syachina MA, Popov VK. Development of Components of Prolonged Action Antibacterial Dosage Forms Using SCF Technologies. RUSSIAN JOURNAL OF PHYSICAL CHEMISTRY B 2021. [DOI: 10.1134/s1990793120070027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
12
|
Markwalter CE, Uralcan B, Pelczer I, Zarzhitsky S, Hecht MH, Prud'homme RK, Debenedetti PG. Stability of Protein Structure during Nanocarrier Encapsulation: Insights on Solvent Effects from Simulations and Spectroscopic Analysis. ACS NANO 2020; 14:16962-16972. [PMID: 33211493 DOI: 10.1021/acsnano.0c06056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The dosing of peptide and protein therapeutics is complicated by rapid clearance from the blood pool and poor cellular membrane permeability. Encapsulation into nanocarriers such as liposomes or polymersomes has long been explored to overcome these limitations, but manufacturing challenges have limited clinical translation by these approaches. Recently, inverse Flash NanoPrecipitation (iFNP) has been developed to produce highly loaded polymeric nanocarriers with the peptide or protein contained within a hydrophilic core, stabilized by a hydrophobic polymer shell. Encapsulation of proteins with higher-order structure requires understanding how processing may affect their conformational state. We demonstrate a combined experimental/simulation approach to characterize protein behavior during iFNP processing steps using the Trp-cage protein TC5b as a model. Explicit-solvent fully atomistic molecular dynamics simulations with enhanced sampling techniques are coupled with two-dimensional heteronuclear multiple-quantum coherence nuclear magnetic resonance spectroscopy (2D-HMQC NMR) and circular dichroism to determine the structure of TC5b during mixed-solvent exposure encountered in iFNP processing. The simulations involve atomistic models of mixed solvents and protein to capture the complexity of the hydrogen bonding and hydrophobic interactions between water, dimethylsulfoxide (DMSO), and the protein. The combined analyses reveal structural unfolding of the protein in 11 M DMSO but confirm complete refolding after release from the polymeric nanocarrier back into an aqueous phase. These results highlight the insights that simulations and NMR provide for the formulation of proteins in nanocarriers.
Collapse
Affiliation(s)
- Chester E Markwalter
- Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States
| | - Betul Uralcan
- Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States
| | - István Pelczer
- Department of Chemistry, Princeton University, Princeton, New Jersey 08544, United States
| | - Shlomo Zarzhitsky
- Department of Chemistry, Princeton University, Princeton, New Jersey 08544, United States
| | - Michael H Hecht
- Department of Chemistry, Princeton University, Princeton, New Jersey 08544, United States
| | - Robert K Prud'homme
- Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States
| | - Pablo G Debenedetti
- Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States
| |
Collapse
|
13
|
Zięba M, Chaber P, Duale K, Martinka Maksymiak M, Basczok M, Kowalczuk M, Adamus G. Polymeric Carriers for Delivery Systems in the Treatment of Chronic Periodontal Disease. Polymers (Basel) 2020; 12:E1574. [PMID: 32679893 PMCID: PMC7407295 DOI: 10.3390/polym12071574] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 07/13/2020] [Accepted: 07/14/2020] [Indexed: 12/18/2022] Open
Abstract
Periodontitis (PD) is a chronic inflammatory disease of periodontal tissues caused by pathogenic microorganisms and characterized by disruption of the tooth-supporting structures. Conventional drug administration pathways in periodontal disease treatment have many drawbacks such as poor biodistribution, low selectivity of the therapeutic effect, burst release of the drug, and damage to healthy cells. To overcome this limitation, controlled drug delivery systems have been developed as a potential method to address oral infectious disease ailments. The use of drug delivery devices proves to be an excellent auxiliary method in improving the quality and effectiveness in periodontitis treatment, which includes inaccessible periodontal pockets. This review explores the current state of knowledge regarding the applications of various polymer-based delivery systems such as hydrogels, liposomes, micro-, and nanoparticles in the treatment of chronic periodontal disease. Furthermore, to present a more comprehensive understanding of the difficulties concerning the treatment of PD, a brief description of the mechanism and development of the disease is outlined.
Collapse
Affiliation(s)
- Magdalena Zięba
- Centre of Polymer and Carbon Materials, Polish Academy of Sciences, 34. M. C. Skłodowska St., 41-800 Zabrze, Poland; (P.C.); (K.D.); (M.M.M.); (M.K.)
| | - Paweł Chaber
- Centre of Polymer and Carbon Materials, Polish Academy of Sciences, 34. M. C. Skłodowska St., 41-800 Zabrze, Poland; (P.C.); (K.D.); (M.M.M.); (M.K.)
| | - Khadar Duale
- Centre of Polymer and Carbon Materials, Polish Academy of Sciences, 34. M. C. Skłodowska St., 41-800 Zabrze, Poland; (P.C.); (K.D.); (M.M.M.); (M.K.)
| | - Magdalena Martinka Maksymiak
- Centre of Polymer and Carbon Materials, Polish Academy of Sciences, 34. M. C. Skłodowska St., 41-800 Zabrze, Poland; (P.C.); (K.D.); (M.M.M.); (M.K.)
| | - Maciej Basczok
- Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, 6 Uniwersytetu Poznańskiego St., 61-614 Poznań, Poland;
| | - Marek Kowalczuk
- Centre of Polymer and Carbon Materials, Polish Academy of Sciences, 34. M. C. Skłodowska St., 41-800 Zabrze, Poland; (P.C.); (K.D.); (M.M.M.); (M.K.)
| | - Grazyna Adamus
- Centre of Polymer and Carbon Materials, Polish Academy of Sciences, 34. M. C. Skłodowska St., 41-800 Zabrze, Poland; (P.C.); (K.D.); (M.M.M.); (M.K.)
| |
Collapse
|
14
|
Thongtham N, Chai‐in P, Unger O, Boonrungsiman S, Suwantong O. Fabrication of chitosan/collagen/hydroxyapatite scaffolds with encapsulatedCissus quadrangularisextract. POLYM ADVAN TECHNOL 2020. [DOI: 10.1002/pat.4879] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
| | - Poowadon Chai‐in
- National Nanotechnology CenterNational Science and Technology Development Agency Pathum Thani Thailand
| | - Onuma Unger
- National Nanotechnology CenterNational Science and Technology Development Agency Pathum Thani Thailand
| | - Suwimon Boonrungsiman
- National Nanotechnology CenterNational Science and Technology Development Agency Pathum Thani Thailand
| | - Orawan Suwantong
- School of ScienceMae Fah Luang University Chiang Rai Thailand
- Center of Chemical Innovation for Sustainability (CIS)Mae Fah Luang University Chiang Rai Thailand
| |
Collapse
|
15
|
Markwalter CE, Pagels RF, Hejazi AN, Gordon AGR, Thompson AL, Prud’homme RK. Polymeric Nanocarrier Formulations of Biologics Using Inverse Flash NanoPrecipitation. AAPS JOURNAL 2020; 22:18. [DOI: 10.1208/s12248-019-0405-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 12/04/2019] [Indexed: 12/20/2022]
|
16
|
Scheiner K, Maas-Bakker RF, Nguyen TT, Duarte AM, Hendriks G, Sequeira L, Duffy GP, Steendam R, Hennink WE, Kok RJ. Sustained Release of Vascular Endothelial Growth Factor from Poly(ε-caprolactone-PEG-ε-caprolactone)- b-Poly(l-lactide) Multiblock Copolymer Microspheres. ACS OMEGA 2019; 4:11481-11492. [PMID: 31460253 PMCID: PMC6681988 DOI: 10.1021/acsomega.9b01272] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 06/18/2019] [Indexed: 05/14/2023]
Abstract
Vascular endothelial growth factor (VEGF) is the major regulating factor for the formation of new blood vessels, also known as angiogenesis. VEGF is often incorporated in synthetic scaffolds to promote vascularization and to enhance the survival of cells that have been seeded in these devices. Such applications require sustained local delivery of VEGF of around 4 weeks for stable blood vessel formation. Most delivery systems for VEGF only provide short-term release for a couple of days, followed by a release phase with very low VEGF release. We now have developed VEGF-loaded polymeric microspheres that provide sustained release of bioactive VEGF for 4 weeks. Blends of two swellable poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone)-b-poly(l-lactide) ([PCL-PEG-PCL]-b-[PLLA])-based multiblock copolymers with different PEG content and PEG molecular weight were used to prepare the microspheres. Loading of the microspheres was established by a solvent evaporation-based membrane emulsification method. The resulting VEGF-loaded microspheres had average sizes of 40-50 μm and a narrow size distribution. Optimized formulations of a 50:50 blend of the two multiblock copolymers had an average VEGF loading of 0.79 ± 0.09%, representing a high average VEGF loading efficiency of 78 ± 16%. These microspheres released VEGF continuously over 4 weeks in phosphate-buffered saline pH 7.4 at 37 °C. This release profile was preserved after repeated and long-term storage at -20 °C for up to 9 months, thereby demonstrating excellent storage stability. VEGF release was governed by diffusion through the water-filled polymer matrix, depending on PEG molecular weight and PEG content of the polymers. The bioactivity of the released VEGF was retained within the experimental error in the 4-week release window, as demonstrated using a human umbilical vein endothelial cells proliferation assay. Thus, the microspheres prepared in this study are suitable for embedment in polymeric scaffolds with the aim of promoting their functional vascularization.
Collapse
Affiliation(s)
- Karina
C. Scheiner
- Department
of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
| | - Roel F. Maas-Bakker
- Department
of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
| | - Thanh T. Nguyen
- InnoCore
Pharmaceuticals B.V., L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands
| | - Ana M. Duarte
- InnoCore
Pharmaceuticals B.V., L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands
| | - Gert Hendriks
- InnoCore
Pharmaceuticals B.V., L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands
| | - Lídia Sequeira
- InnoCore
Pharmaceuticals B.V., L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands
| | - Garry P. Duffy
- Discipline
of Anatomy, School of Medicine, National
University of Ireland Galway, University Road, H91 TK33 Galway, Ireland
| | - Rob Steendam
- InnoCore
Pharmaceuticals B.V., L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands
| | - Wim E. Hennink
- Department
of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
| | - Robbert J. Kok
- Department
of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
- E-mail: . Phone: +31 620275995. Fax: +31 30 251789
| |
Collapse
|
17
|
Kloypan C, Prapan A, Suwannasom N, Chaiwaree S, Kaewprayoon W, Steffen A, Xiong Y, Baisaeng N, Georgieva R, Bäumler H. Improved oxygen storage capacity of haemoglobin submicron particles by one-pot formulation. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2018; 46:S964-S972. [DOI: 10.1080/21691401.2018.1521819] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Chiraphat Kloypan
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Division of Clinical Immunology and Transfusion Sciences, School of Allied Health Sciences, University of Phayao, Phayao, Thailand
| | - Ausanai Prapan
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Radiological Technology, Naresuan University, Phitsanulok, Thailand
| | - Nittiya Suwannasom
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Division of Biochemistry and Nutrition, School of Medical Sciences, University of Phayao, Phayao, Thailand
| | - Saranya Chaiwaree
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Pharmaceutical Technology, Payap University, Chiang Mai, Thailand
| | - Waraporn Kaewprayoon
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Pharmaceutical Technology, Payap University, Chiang Mai, Thailand
| | - Axel Steffen
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Yu Xiong
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Nuttakorn Baisaeng
- Division of Pharmaceutical Sciences, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
| | - Radostina Georgieva
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Medical Physics, Biophysics and Radiology, Trakia University, Stara Zagora, Bulgaria
| | - Hans Bäumler
- Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
18
|
Ariza-Sáenz M, Espina M, Calpena A, Gómara MJ, Pérez-Pomeda I, Haro I, García ML. Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide. Mol Pharm 2018; 15:5005-5018. [PMID: 30226777 DOI: 10.1021/acs.molpharmaceut.8b00609] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
New therapeutic alternatives to fight against the spread of HIV-1 are based on peptides designed to inhibit the early steps of HIV-1 fusion in target cells. However, drawbacks, such as bioavailability, short half-life, rapid clearance, and poor ability to cross the physiological barriers, make such peptides unattractive for the pharmaceutical industry. Here we developed, optimized, and characterized polymeric nanoparticles (NPs) coated with glycol chitosan to incorporate and release an HIV-1 fusion inhibitor peptide (E1) inside the vaginal mucosa. The NPs were prepared by a modified double emulsion method, and optimization was carried out by a factorial design. In vitro, ex vivo, and in vivo studies were carried out to evaluate the optimized formulation. The results indicate that the physicochemical features of these NPs enable them to incorporate and release HIV fusion inhibitor peptides to the vaginal mucosa before the fusion step takes place.
Collapse
Affiliation(s)
- Martha Ariza-Sáenz
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry , University of Barcelona , Av. Joan XXIII, 27-31 , Barcelona 08028 , Spain.,Unit of Synthesis and Biomedical Application of Peptides, Department of Biomedical Chemistry , IQAC-CSIC , Jordi Girona 18 , 08034 Barcelona , Spain
| | - Marta Espina
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry , University of Barcelona , Av. Joan XXIII, 27-31 , Barcelona 08028 , Spain
| | - Ana Calpena
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry , University of Barcelona , Av. Joan XXIII, 27-31 , Barcelona 08028 , Spain
| | - María J Gómara
- Unit of Synthesis and Biomedical Application of Peptides, Department of Biomedical Chemistry , IQAC-CSIC , Jordi Girona 18 , 08034 Barcelona , Spain
| | - Ignacio Pérez-Pomeda
- Unit of Synthesis and Biomedical Application of Peptides, Department of Biomedical Chemistry , IQAC-CSIC , Jordi Girona 18 , 08034 Barcelona , Spain
| | - Isabel Haro
- Unit of Synthesis and Biomedical Application of Peptides, Department of Biomedical Chemistry , IQAC-CSIC , Jordi Girona 18 , 08034 Barcelona , Spain
| | - María Luisa García
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry , University of Barcelona , Av. Joan XXIII, 27-31 , Barcelona 08028 , Spain
| |
Collapse
|
19
|
Lee PW, Pokorski JK. Poly(lactic-co-glycolic acid) devices: Production and applications for sustained protein delivery. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2018; 10:e1516. [PMID: 29536634 PMCID: PMC6136991 DOI: 10.1002/wnan.1516] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/14/2017] [Revised: 01/30/2018] [Accepted: 02/14/2018] [Indexed: 12/12/2022]
Abstract
Injectable or implantable poly(lactic-co-glycolic acid) (PLGA) devices for the sustained delivery of proteins have been widely studied and utilized to overcome the necessity of repeated administrations for therapeutic proteins due to poor pharmacokinetic profiles of macromolecular therapies. These devices can come in the form of microparticles, implants, or patches depending on the disease state and route of administration. Furthermore, the release rate can be tuned from weeks to months by controlling the polymer composition, geometry of the device, or introducing additives during device fabrication. Slow-release devices have become a very powerful tool for modern medicine. Production of these devices has initially focused on emulsion-based methods, relying on phase separation to encapsulate proteins within polymeric microparticles. Process parameters and the effect of additives have been thoroughly researched to ensure protein stability during device manufacturing and to control the release profile. Continuous fluidic production methods have also been utilized to create protein-laden PLGA devices through spray drying and electrospray production. Thermal processing of PLGA with solid proteins is an emerging production method that allows for continuous, high-throughput manufacturing of PLGA/protein devices. Overall, polymeric materials for protein delivery remain an emerging field of research for the creation of single administration treatments for a wide variety of disease. This review describes, in detail, methods to make PLGA devices, comparing traditional emulsion-based methods to emerging methods to fabricate protein-laden devices. This article is categorized under: Biology-Inspired Nanomaterials > Protein and Virus-Based Structures Implantable Materials and Surgical Technologies > Nanomaterials and Implants Biology-Inspired Nanomaterials > Peptide-Based Structures.
Collapse
Affiliation(s)
- Parker W. Lee
- Department of Macromolecular Science and Engineering, School of Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Jonathan K. Pokorski
- Department of Macromolecular Science and Engineering, School of Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| |
Collapse
|
20
|
Grudén S, Hassan M, Axén N. Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release drug formulations. J Drug Deliv Sci Technol 2018. [DOI: 10.1016/j.jddst.2018.06.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
21
|
Duque L, Körber M, Bodmeier R. Improving release completeness from PLGA-based implants for the acid-labile model protein ovalbumin. Int J Pharm 2018; 538:139-146. [DOI: 10.1016/j.ijpharm.2018.01.026] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 01/09/2018] [Accepted: 01/13/2018] [Indexed: 12/20/2022]
|
22
|
Duque L, Körber M, Bodmeier R. Impact of change of matrix crystallinity and polymorphism on ovalbumin release from lipid-based implants. Eur J Pharm Sci 2018; 117:128-137. [PMID: 29452211 DOI: 10.1016/j.ejps.2018.02.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 01/29/2018] [Accepted: 02/12/2018] [Indexed: 11/28/2022]
Abstract
The objectives of this study were to prepare lipid-based implants by hot melt extrusion (HME) for the prolonged release of ovalbumin (OVA), and to relate protein release to crystallinity and polymorphic changes of the lipid matrix. Two lipids, glycerol tristearate and hydrogenated palm oil, with different composition and degree of crystallinity were studied. Solid OVA was dispersed within the lipid matrixes, which preserved its stability during extrusion. This was partially attributed to a protective effect of the lipidic matrix. The incorporation of OVA decreased the mechanical strength of the implants prepared with the more crystalline matrix, glycerol tristearate, whereas it remained comparable for the hydrogenated palm oil because of stronger physical and non-covalent interactions between the protein and this lipid. This was also the reason for the faster release of OVA from the glycerol tristearate matrix when compared to the hydrogenated palm oil (8 vs. 28 weeks). Curing induced and increased crystallinity, and changes in the release rate, especially for the more crystalline matrix. In this case, both an increase and a decrease in release, were observed depending on the tempering condition. Curing at higher temperatures induced a melt-mediated crystallization and solid state transformation of the glycerol tristearate matrix and led to rearrangements of the inner structure with the formation of larger pores, which accelerated the release. In contrast, changes in the hydrogenated palm oil under the same curing conditions were less noticeable leading to a more robust formulation, because of less polymorphic changes over time. This study helps to understand the effect of lipid matrix composition and crystallinity degree on the performance of protein-loaded implants, and to establish criteria for the selection of a lipid carrier depending on the release profile desired.
Collapse
Affiliation(s)
- Luisa Duque
- College of Pharmacy, Freie Universität Berlin, Kelchstrasse 31, 12169 Berlin, Germany
| | - Martin Körber
- College of Pharmacy, Freie Universität Berlin, Kelchstrasse 31, 12169 Berlin, Germany; Pensatech Pharma GmbH, Kelchstrasse 31, 12169 Berlin, Germany
| | - Roland Bodmeier
- College of Pharmacy, Freie Universität Berlin, Kelchstrasse 31, 12169 Berlin, Germany.
| |
Collapse
|
23
|
Inverse Flash NanoPrecipitation for Biologics Encapsulation: Understanding Process Losses via an Extraction Protocol. ACTA ACUST UNITED AC 2017. [DOI: 10.1021/bk-2017-1271.ch012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
24
|
Dai J, Long W, Liang Z, Wen L, Yang F, Chen G. A novel vehicle for local protein delivery to the inner ear: injectable and biodegradable thermosensitive hydrogel loaded with PLGA nanoparticles. Drug Dev Ind Pharm 2017; 44:89-98. [PMID: 28851247 DOI: 10.1080/03639045.2017.1373803] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Delivery of biomacromolecular drugs into the inner ear is challenging, mainly because of their inherent instability as well as physiological and anatomical barriers. Therefore, protein-friendly, hydrogel-based delivery systems following local administration are being developed for inner ear therapy. Herein, biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing interferon α-2 b (IFN α-2 b) were loaded in chitosan/glycerophosphate (CS/GP)-based thermosensitive hydrogel for IFN delivery by intratympanic injection. The injectable hydrogel possessed a physiological pH and formed semi-solid gel at 37 °C, with good swelling and deswelling properties. The CS/GP hydrogel could slowly degrade as visualized by scanning electron microscopy (SEM). The presence of NPs in CS/GP gel largely influenced in vitro drug release. In the guinea pig cochlea, a 1.5- to 3-fold increase in the drug exposure time of NPs-CS/GP was found than those of the solution, NPs and IFN-loaded hydrogel. Most importantly, a prolonged residence time was attained without obvious histological changes in the inner ear. This biodegradable, injectable, and thermosensitive NPs-CS/GP system may allow longer delivery of protein drugs to the inner ear, thus may be a potential novel vehicle for inner ear therapy.
Collapse
Affiliation(s)
- Juan Dai
- a School of Pharmacy , Guangdong Pharmaceutical University , Guangzhou , China.,b Guangdong Provincial Key Laboratory of Advanced Drug Delivery , Guangdong Pharmaceutical University , Guangzhou , China
| | - Wei Long
- a School of Pharmacy , Guangdong Pharmaceutical University , Guangzhou , China.,b Guangdong Provincial Key Laboratory of Advanced Drug Delivery , Guangdong Pharmaceutical University , Guangzhou , China
| | - Zhongping Liang
- a School of Pharmacy , Guangdong Pharmaceutical University , Guangzhou , China.,b Guangdong Provincial Key Laboratory of Advanced Drug Delivery , Guangdong Pharmaceutical University , Guangzhou , China
| | - Lu Wen
- a School of Pharmacy , Guangdong Pharmaceutical University , Guangzhou , China
| | - Fan Yang
- a School of Pharmacy , Guangdong Pharmaceutical University , Guangzhou , China.,b Guangdong Provincial Key Laboratory of Advanced Drug Delivery , Guangdong Pharmaceutical University , Guangzhou , China
| | - Gang Chen
- a School of Pharmacy , Guangdong Pharmaceutical University , Guangzhou , China.,b Guangdong Provincial Key Laboratory of Advanced Drug Delivery , Guangdong Pharmaceutical University , Guangzhou , China
| |
Collapse
|
25
|
Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects. Eur J Pharm Sci 2017; 104:315-325. [DOI: 10.1016/j.ejps.2017.03.050] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Revised: 03/06/2017] [Accepted: 03/14/2017] [Indexed: 02/07/2023]
|
26
|
Li Q, Cai T, Huang Y, Xia X, Cole SPC, Cai Y. A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs. NANOMATERIALS 2017; 7:nano7060122. [PMID: 28554993 PMCID: PMC5485769 DOI: 10.3390/nano7060122] [Citation(s) in RCA: 119] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 05/09/2017] [Accepted: 05/16/2017] [Indexed: 01/17/2023]
Abstract
Nanostructured lipid carriers (NLCs) are modified solid lipid nanoparticles (SLNs) that retain the characteristics of the SLN, improve drug stability and loading capacity, and prevent drug leakage. Polymer nanoparticles (PNPs) are an important component of drug delivery. These nanoparticles can effectively direct drug delivery to specific targets and improve drug stability and controlled drug release. Lipid–polymer nanoparticles (PLNs), a new type of carrier that combines liposomes and polymers, have been employed in recent years. These nanoparticles possess the complementary advantages of PNPs and liposomes. A PLN is composed of a core–shell structure; the polymer core provides a stable structure, and the phospholipid shell offers good biocompatibility. As such, the two components increase the drug encapsulation efficiency rate, facilitate surface modification, and prevent leakage of water-soluble drugs. Hence, we have reviewed the current state of development for the NLCs’, PNPs’, and PLNs’ structures, preparation, and applications over the past five years, to provide the basis for further study on a controlled release drug delivery system.
Collapse
Affiliation(s)
- Qianwen Li
- College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Tiange Cai
- College of Life Sciences, Liaoning University, Shenyang 110036, China.
| | - Yinghong Huang
- GuangzhouGuoyu Pharmaceutical Technology Co., Ltd., Guangzhou 510632, China.
| | - Xi Xia
- College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Susan P C Cole
- Division of Cancer Biology and Genetics, Queen's University Cancer Research Institute, Kingston, ON K7L 3N6, Canada.
| | - Yu Cai
- College of Pharmacy, Jinan University, Guangzhou 510632, China.
- Cancer Research Institute of Jinan University, Guangzhou 510632, China.
| |
Collapse
|
27
|
Radwan MA, AlQuadeib BT, Šiller L, Wright MC, Horrocks B. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. Drug Deliv 2017; 24:40-50. [PMID: 28155565 PMCID: PMC8247729 DOI: 10.1080/10717544.2016.1228715] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Amphotericin B (AMB) is used most commonly in severe systemic life-threatening fungal infections. There is currently an unmet need for an efficacious (AMB) formulation amenable to oral administration with better bioavailability and lower nephrotoxicity. Novel PEGylated polylactic-polyglycolic acid copolymer (PLGA-PEG) nanoparticles (NPs) formulations of AMB were therefore studied for their ability to kill Candida albicans (C. albicans). The antifungal activity of AMB formulations was assessed in C. albicans. Its bioavalability was investigated in nine groups of rats (n = 6). Toxicity was examined by an in vitro blood hemolysis assay, and in vivo nephrotoxicity after single and multiple dosing for a week by blood urea nitrogen (BUN) and plasma creatinine (PCr) measurements. The MIC of AMB loaded to PLGA-PEG NPs against C. albicans was reduced two to threefold compared with free AMB. Novel oral AMB delivery loaded to PLGA-PEG NPs was markedly systemically available compared to Fungizone® in rats. The addition of 2% of GA to the AMB formulation significantly (p < 0.05) improved the bioavailability from 1.5 to 10.5% and the relative bioavailability was > 790% that of Fungizone®. The novel AMB formulations showed minimal toxicity and better efficacy compared to Fungizone®. No nephrotoxicity in rats was detected after a week of multiple dosing of AMB NPs based on BUN and PCr, which remained at normal levels. An oral delivery system of AMB-loaded to PLGA-PEG NPs with better efficacy and minimal toxicity was formulated. The addition of glycyrrhizic acid (GA) to AMB NPs formulation resulted in a significant oral absorption and improved bioavailability in rats.
Collapse
Affiliation(s)
- Mahasen A Radwan
- a Department of Pharmaceutical Practice , College of Pharmacy, Princess Nourah bint Abdelrahman University , Riyadh , Saudi Arabia.,b Department of Pharmaceutics and Pharmaceutical Technology , College of Pharmacy, Egyptian Russian University , Bader City , Egypt
| | - Bushra T AlQuadeib
- c Department of Pharmaceutics , College of Pharmacy, King Saud University , Riyadh , Saudi Arabia
| | - Lidija Šiller
- d School of Chemical Engineering and Advanced Materials, Herschel Building, Newcastle University , Newcastle upon Tyne , UK , and
| | - Matthew C Wright
- e Institute of Cellular Medicine, Leech Building, Medical School, Newcastle University , Newcastle upon Tyne , UK
| | - Benjamin Horrocks
- d School of Chemical Engineering and Advanced Materials, Herschel Building, Newcastle University , Newcastle upon Tyne , UK , and
| |
Collapse
|
28
|
Chevigne A, Delhalle S, Counson M, Beaupain N, Rybicki A, Verschueren C, Staub T, Schmit JC, Seguin-Devaux C, Deroo S. Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller. AIDS 2016; 30:377-82. [PMID: 26760231 DOI: 10.1097/qad.0000000000000925] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVES The recent identification of neutralizing antibodies able to prevent viral rebound reemphasized the interest in humoral immune responses to control HIV-1 infection. In this study, we characterized HIV-1-inhibiting sequences from heavy-chain complementary determining region 3 (HCDR3) repertoires of a viremic controller. DESIGN AND METHODS IgM and IgG-derived HCDR3 repertoires of a viremic controller presenting plasma-neutralizing activity and characterized by over 20 years of infection with a stable CD4 T-cell count were displayed on filamentous phage to identify HCDR3 repertoire-derived peptides inhibiting HIV-1 entry. RESULTS Screening of phage libraries against recombinant gp120 led to the identification of an HCDR3-derived peptide sequence (LRTV-1) displaying antiviral properties against both X4 and R5 viruses. The interaction of LRTV-1 with gp120 was enhanced upon CD4 binding and sequence comparison revealed homology between LRTV-1 and the second extracellular loop of C-X-C chemokine receptor type 4 (CXCR4) (11/23) and the N-terminus of C-C chemokine receptor type 5 (CCR5) (7/23). Alanine scanning experiments identified different clusters of residues critical for interaction with the viral envelope protein. CONCLUSIONS LRTV-1 peptide is to date the smallest human HCDR3 repertoire-derived peptide identified by phage display inhibiting HIV entry of R5 and X4 viruses. This peptide recognizes a CD4-dependent gp120 epitope critical for coreceptor binding and mimics the surface of CXCR4 and CCR5. Our data emphasize the potential of human HCDR3 immune repertoires as sources of small biologically active peptides for HIV cure.
Collapse
|
29
|
|
30
|
Pagels RF, Prud'homme RK. Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics. J Control Release 2015; 219:519-535. [PMID: 26359125 DOI: 10.1016/j.jconrel.2015.09.001] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Revised: 09/02/2015] [Accepted: 09/03/2015] [Indexed: 01/10/2023]
Abstract
Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the pharmaceutical marketplace. However, there are still unmet needs in improving the delivery of biologics. Injectable polymeric nanoparticles and microparticles capable of releasing proteins and peptides over time periods as long as weeks or months have been a major focus in the effort to decrease the frequency of administration. These particle systems fit broadly into two categories: those composed of hydrophilic and those composed of hydrophobic polymeric scaffolds. Here we review the factors that contribute to the slow and controlled release from each class of particle, as well as the effects of synthesis parameters and product design on the loading, encapsulation efficiency, biologic integrity, and release profile. Generally, hydrophilic scaffolds are ideal for large proteins while hydrophobic scaffolds are more appropriate for smaller biologics without secondary structure. Here we also introduce a Flash NanoPrecipitation method that has been adopted for encapsulating biologics in nanoparticles (40-200nm) at high loadings (50-75wt.%) and high encapsulation efficiencies. The hydrophilic gel interior and hydrophobic shell provide an opportunity to combine the best of both classes of injectable polymeric depots.
Collapse
Affiliation(s)
- Robert F Pagels
- Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ 08544, United States
| | - Robert K Prud'homme
- Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ 08544, United States.
| |
Collapse
|